ClinicalTrials.gg
CompletedNCT04622605Updated Feb 16, 2022

Hydrus Microstent and Lens Extraction for the Treatment of Primary Angle-Closure Glaucoma

An interventional study of Trabecular bypass and Schlemm's canal stent in Primary Angle Closure Glaucoma and Primary Angle Closure, sponsored by Asian Eye Institute. Completed at 1 site in Philippines. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2022-02-16.

Sponsored by Asian Eye Institute · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 4 months after the study started (first participant enrolled Jun 2017, registered Nov 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Study summary

This study is a prospective evaluation of the Hydrus Microstent for the treatment of Primary Angle Closure (PAC) and Primary Angle Closure Glaucoma (PACG) with adjunctive cataract. A total of 20 subjects will be successfully treated with one Hydrus device after completion of cataract extraction with phacoemulsification followed by IOL replacement (HMS cohort), and 10 eyes will be treated with phacoemulsification cataract extraction and IOL replacement only (PCS group). Since cataract surgery is standard of care for this condition, eligible fellow eyes from the HMS cohort may be enrolled into the PCS group. To avoid selection bias in this non-randomized study, the first 20 consecutive qualifying subjects will be treated with Hydrus and the next 10 consecutive qualifying eyes will be treated with cataract surgery only.

Read the detailed description

The objective of this study is to assess the effectiveness of the Hydrus Microstent for lowering intraocular pressure in patients with PAC or PACG. The addition of the Hydrus is expected to lower IOP and medication dependency, and thus reduce the risk of progression of glaucoma. The PCS group will provide a control group to assess the magnitude of the Hydrus treatment effect on IOP, medications, and safety.

Upon successfully meeting the study inclusion/exclusion criteria at both the screening and baseline visits, the subject will be scheduled for surgery. Follow up will be continued for 1 year post surgery, and will include assessments of the subject's IOP, ocular health, and visual acuity status. Visits will be conducted at 1, 7, 30, 90, 180, and 365 days.

A 20% drop in IOP in response to therapy is considered clinically meaningful. The study treatment will be considered successful if a patient can obtain this response in IOP using the same or a fewer number of medications as pre-operative baseline.

02

Conditions studied

  • Primary Angle Closure Glaucoma
  • Primary Angle Closure
03

In context

Glaucoma, Angle-Closure

91 studies on the registry are indexed under Glaucoma, Angle-Closure; 17 are open to participants now.

This study's enrollment of 31 is below the median of 57 across 58 interventional studies indexed under Glaucoma, Angle-Closure.

Browse Glaucoma, Angle-Closure studies →

Lead sponsor

This is the only study on the registry with Asian Eye Institute as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Pre-Operative Inclusion Criteria

  1. Male and Female patients at least 40 years of age.
  2. An operable age-related cataract with visual impairment or glare, eligible for phacoemulsification.
  3. Subjects with diagnosed primary angle-closure (PAC; defined as appositional or synechial irido-trabecular contact of 90 degrees or more on gonionscopy) OR primary angle-closure glaucoma (PACG; defined as PAC with documented glaucomatous optic neuropathy and/or reproducible glaucomatous visual field defect), and on > or = 1 glaucoma medication with IOP > or = 21mmHg at both preoperative visits.
  4. PAC or PACG subjects that are newly diagnosed, or unmedicated (newly diagnosed or non-compliant patient not using medication for > 30 days), with IOP > or = 24mmHg at both preoperative visits.

The subject is able to understand the requirements of the study and is willing to provide written , follow study instructions, and comply with all study procedures.

Intraoperative Inclusion Critera

  1. An intact and centered capsulorhexis.
  2. An intact posterior capsular bag.
  3. A well-centered IOL implant placed in the capsular bag.
  4. A clear view and visualization of the angle with direct gonioscopy.
  5. No evidence of zonular dehiscence/rupture (uncomplicated cataract extraction)

Exclusion criteria

Exclusion Criteria:

  1. Pseudophakia in the intended study eye
  2. All forms of glaucoma other than primary angle-closure (i.e. all open-angle glaucoma including primary open-angle, pseudoexfoliative, or pigmentary glaucoma; neovascular, uveitic, traumatic, induced, lens induced, or glaucoma associated with increased episcleral venous pressure; congenital or developmental glaucoma).
  3. Secondary angle-closure glaucoma
  4. Advanced glaucoma, defined as visual field mean deviation worse than -15 dB, or cup-to-disc ration > or = 0.9.
  5. Visual field depression within the central 5 degrees of fixation, on pattern deviation probability plot.
  6. Eyes with an anticipated need for incisional glaucoma surgery (e.g. trabeculectomy or tube shunt) within the 12-month follow-up period.
  7. Central corneal thickness >620 or \<490 microns.
  8. Axial length \< or = 19 mm (nanophthalmos).
  9. Previous incisional glaucoma surgery in the study eye, including trabeculectomy, tube shunt, and non-penetrating procedures such as deep sclerectomy, viscocanalostomy or canaloplasty.
  10. Plateau iris syndrome.
  11. History of complicated intraocular surgery.
  12. Previous MIGS surgery in the study eye.
  13. Proliferative diabetic retinopathy.
  14. Previous surgery for retinal detachment.
  15. corneal dystrophy (e.g. Fuch's Dystrophy).
  16. Best-corrected visual acuity in the fellow eye worse than 20/200.
  17. Previous corneal surgery.
  18. Previous refractive surgery.
  19. Degenerative visual disorders such as exudative age-related macular degeneration.
  20. Clinically significant ocular inflammation or infection within thirty days prior to screening.
  21. Uncontrolled systemic disease that in the opinion of the investigator would put the subject's health at risk and/or prevent the subject from completing all study visits.
  22. Pregnant or nursing females.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Treatment Group

    Cataract extraction and intraocular lens placement with combined placement of glaucoma microstent

    Device: Trabecular bypass and Schlemm's canal stent

Interventions

  • DeviceTrabecular bypass and Schlemm's canal stent

    ab interno Microstent placement after cataract surgery

    Also known as: Hydrus Microstent

06

What researchers measure

Primary outcomes

  1. Reduction in IOP

    Proportion of subjects with \> or = 20% reduction of IOP while maintaining the same or fewer number of glaucoma medications compared with baseline, measured by Goldmann applanation tonometry

    Time frame: 12 months

Secondary outcomes

  1. Change in IOP

    Change in IOP compared to baseline IOP regardless of the number of glaucoma medications

    Time frame: 12 months

07

Study locations

1 site
  • Asian Eye Institute
    Makati City, Metro Manila 1200, Philippines
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04622605
Lead sponsor
Asian Eye Institute
Collaborators
Ivantis, Inc.
Responsible party
Robert Edward T. Ang (Principal Investigator, Asian Eye Institute) — Principal investigator
First posted
Nov 10, 2020
Start date
Jun 13, 2017
Primary completion
Sep 1, 2021
Completion
Dec 23, 2021
Last update
Feb 16, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion